Picture1.jpg
GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology
April 15, 2021 11:59 ET | GigaGen, Inc.
SOUTH SAN FRANCISCO, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and...
Picture1.jpg
GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
March 23, 2021 10:00 ET | GigaGen, Inc.
SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- GigaGen, a biotechnology company advancing transformative antibody drugs for immune deficiency, infectious diseases, transplant...
GigaGen_Inline_FullColor_RGB[1].jpg
GigaGen Announces Publication in the Peer-Reviewed Journal mAbs
October 20, 2020 10:17 ET | GigaGen, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and...
GigaGen_Inline_FullColor_RGB[1].jpg
GigaGen Initiates Large-Scale Manufacturing of its First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050
September 09, 2020 10:17 ET | GigaGen, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and...
GigaGen_Inline_FullColor_RGB[1].jpg
GigaGen Announces Publication of Research Describing a New Class of Drugs, Recombinant Hyperimmunes, Including its Novel COVID-19 Therapy, GIGA-2050
August 10, 2020 10:17 ET | GigaGen, Inc.
GIGA-2050 is like a "recombinant convalescent serum," enabling production of millions of doses of drug from a few donorsGIGA-2050 is 100-fold more potent than convalescent serum and comprises 12,500...
GigaGen_Inline_FullColor_RGB[1].jpg
GigaGen to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
July 29, 2020 09:30 ET | GigaGen, Inc.
SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and...
GigaGen_Inline_FullColor_RGB[1].jpg
GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19
March 30, 2020 10:17 ET | GigaGen, Inc.
rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin) in development to treat high-risk and severely ill individuals infected with COVID-19Overcomes limitations of plasma-based polyclonal...